Literature DB >> 28090528

Uncovering first molecular mechanisms of secondary resistance against PD-1 blockade.

Selma Ugurel1.   

Abstract

Year:  2016        PMID: 28090528      PMCID: PMC5220036          DOI: 10.21037/atm.2016.11.05

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  8 in total

1.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

2.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

Review 3.  Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

Authors:  David McDermott; Celeste Lebbé; F Stephen Hodi; Michele Maio; Jeffrey S Weber; Jedd D Wolchok; John A Thompson; Charles M Balch
Journal:  Cancer Treat Rev       Date:  2014-07-07       Impact factor: 12.111

4.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

Review 5.  Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Authors:  Selma Ugurel; Joachim Röhmel; Paolo A Ascierto; Keith T Flaherty; Jean Jacques Grob; Axel Hauschild; James Larkin; Georgina V Long; Paul Lorigan; Grant A McArthur; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Claus Garbe
Journal:  Eur J Cancer       Date:  2015-12-17       Impact factor: 9.162

Review 6.  Checkpoint Blockade for the Treatment of Advanced Melanoma.

Authors:  Margaret K Callahan; Catherine R Flaherty; Michael A Postow
Journal:  Cancer Treat Res       Date:  2016

Review 7.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

8.  Genetic evolution of T-cell resistance in the course of melanoma progression.

Authors:  Antje Sucker; Fang Zhao; Birgit Real; Christina Heeke; Nicola Bielefeld; Stefan Maβen; Susanne Horn; Iris Moll; Raffaela Maltaner; Peter A Horn; Bastian Schilling; Francesco Sabbatino; Volker Lennerz; Matthias Kloor; Soldano Ferrone; Dirk Schadendorf; Christine S Falk; Klaus Griewank; Annette Paschen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.